Truist initiated coverage of MannKind (MNKD) with a Buy rating and $9 price target MannKind continues to execute with their technology, with both Afrezza and Tyvaso DPI, and the recent acquisition of scPharmaceuticals adds another topline driver, Furoscix, for fluid overload, the analyst tells investors in a research note. MannKind’s orphan lung pipeline continues to advance for longer-term diversification and growth for the company, Truist says.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind price target lowered to $10 from $15 at Oppenheimer
- MannKind’s Strategic Advancements and Product Potential Justify Buy Rating Despite MNKD-101 Discontinuation
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- H.C. Wainwright remains bullish on MannKind despite disappointing MNKD-101 news
- MannKind’s Resilience and Growth Potential: A Buy Rating Amid Setbacks and Opportunities